MergerLinks Header Logo

Submit Deal

Submit Deal

Cover Image EVENTIDE ASSET MANAGEMENT
EVENTIDE ASSET MANAGEMENT

EVENTIDE ASSET MANAGEMENT

HQ - Boston

Summary

Evantide Asset Management provides investments for individuals, financial advisors, and institutions.

Deals Overview

Total Deals12
Valued Deals12
Total Value£6,387M
Avg. Deal Size£532M

Market Context

Deals (12)

Service Providers

Relationships

Portfolio

Team

Sort

United Kingdom
Biotechnology
AcquisitionVenture CapitalPrivatePrivate EquityMinority
Freeline Therapeutics

target

Freeline Therapeutics

Wellington Management

bidder

Wellington Management

£91m

9 dealmakers

United States
Pharmaceuticals
PrivateVenture CapitalAcquisitionMinorityPrivate EquityCross Border
ANNEXON

target

ANNEXON

Adage Capital Management

bidder

Adage Capital Management

£81m

16 dealmakers

Switzerland
Biotechnology
Cross BorderAcquisitionPrivate EquityPrivateMinorityVenture Capital
VECTIVBIO

target

VECTIVBIO

Cormorant Asset Management

bidder

Cormorant Asset Management

£84m

35 dealmakers

Switzerland
Pharmaceuticals
Cross BorderMajorityDe-SPACReverse TakeoverPrivate EquityMergerPrivateAcquisition
Roivant Sciences

target

Roivant Sciences

Montes Archimedes Acquisition Corp

bidder

Montes Archimedes Acquisition Corp

£5,280m

39 dealmakers

United States
Biotechnology
Venture CapitalMinorityCross BorderPrivatePrivate EquityAcquisition
Lexeo Therapeutics

target

Lexeo Therapeutics

D1 Capital Partners

bidder

D1 Capital Partners

£72m

15 dealmakers

United States
Biotechnology
MinorityPrivateCross BorderPrivate EquityVenture CapitalAcquisition
Shoreline Biosciences

target

Shoreline Biosciences

Eventide Asset Management

bidder

Eventide Asset Management

£102m

5 dealmakers

United States
Biotechnology
PrivatePrivate EquityCross BorderMinorityAcquisitionVenture Capital
Korro Bio

target

Korro Bio

Atlas Venture

bidder

Atlas Venture

£85m

14 dealmakers

United States
Biotechnology
MinorityAcquisitionPrivate EquityCross BorderPrivateVenture Capital
METAGENOMI

target

METAGENOMI

MODERNA

bidder

MODERNA

£129m

17 dealmakers

United States
Biotechnology
Venture CapitalAcquisitionCross BorderMinorityPrivate EquityPrivate
Biosplice Therapeutics

target

Biosplice Therapeutics

Sands Capital

bidder

Sands Capital

£104m

5 dealmakers

United States
Biotechnology
Venture CapitalPrivateAcquisitionPrivate EquityMinorityCross Border
Flare Therapeutics

target

Flare Therapeutics

Memorial Sloan Kettering Cancer Center

bidder

Memorial Sloan Kettering Cancer Center

£100m

6 dealmakers

United States
Biotechnology
AcquisitionMajorityPublicPrivate EquityDomestic
Frequency Therapeutics

target

Frequency Therapeutics

Korro Bio

bidder

Korro Bio

£129m

32 dealmakers

United States
Pharmaceuticals
MinorityPrivateVenture CapitalAcquisitionPrivate EquityDomestic
Sudo Biosciences

target

Sudo Biosciences

Enavate Sciences

bidder

Enavate Sciences

£123m

7 dealmakers

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US